Line 18: |
Line 18: |
| == Resources from the international guideline community == | | == Resources from the international guideline community == |
| | | |
− | === Example disclosure of interest forms: === | + | === Examples of disclosure of interest forms: === |
| * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form] | | * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i12 American Thoracic Society disclosure of interests form] |
− | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines-form.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for panel members] |
− | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-clinician_coi-declaration.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians] |
− | * CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups | + | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-patientad-coi-declaratio.doc CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups] |
− | * Canadian Task Force on Preventive Healthcare disclosure of interest form (see Appendix 1) | + | * [https://canadiantaskforce.ca/wp-content/uploads/2016/12/procedural-manual-en_2014_Archived.pdf Canadian Task Force on Preventive Healthcare disclosure of interest form] (see Appendix 1) |
− | * Cochrane Collaboration disclosure of interest form | + | * [https://community.cochrane.org/sites/default/files/uploads/EPPR/Cochrane-COI-disclosure-form.pdf Cochrane Collaboration disclosure of interest form] |
| * US FDA financial disclosure report – Executive Branch | | * US FDA financial disclosure report – Executive Branch |
| * US FDA financial disclosure report – Special Government Employees | | * US FDA financial disclosure report – Special Government Employees |
Line 40: |
Line 40: |
| * United States Preventive Services Task Force (USPSTF) disclosure of interest form | | * United States Preventive Services Task Force (USPSTF) disclosure of interest form |
| | | |
− | === Example algorithms/process maps for COI management === | + | === Examples of algorithms/process maps for COI management === |
| * American Thoracic Society COI resolution procedure | | * American Thoracic Society COI resolution procedure |
| * CADTH pan-Canadian Oncology Drug Review COI management overview (Appendix A) | | * CADTH pan-Canadian Oncology Drug Review COI management overview (Appendix A) |
Line 48: |
Line 48: |
| * National Institute of Health and Care Excellence (UK) process for declaring interests (Appendix A) | | * National Institute of Health and Care Excellence (UK) process for declaring interests (Appendix A) |
| | | |
− | === Example of published summaries of disclosures === | + | === Examples of published summaries of disclosures === |
| o Australian Technical Advisory Group on Immunisation disclosure summary | | o Australian Technical Advisory Group on Immunisation disclosure summary |
| | | |
| o Haute Authorité de Santé (France) examples of public disclosures of experts | | o Haute Authorité de Santé (France) examples of public disclosures of experts |
| | | |
− | === Example scales for assessing significance of COI === | + | === Examples of scales for assessing the significance of COI === |
| o American Thoracic Society method for evaluating significance of COI | | o American Thoracic Society method for evaluating significance of COI |
| | | |
Line 60: |
Line 60: |
| o USPSTF COI significance and management table | | o USPSTF COI significance and management table |
| | | |
− | === GIN principles paper === | + | === [https://annals.org/aim/fullarticle/2450219/guidelines-international-network-principles-disclosure-interests-management-conflicts-guidelines GIN principles paper] === |
| | | |
| == References == | | == References == |
| <references /> | | <references /> |